| # | Title | Journal | Year | Citations |
|---|
| 1 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial | Lancet Oncology, The | 2014 | 864 |
| 2 | Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology | 2017 | 792 |
| 3 | A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844 | International Journal of Radiation Oncology Biology Physics | 1996 | 641 |
| 4 | Fungal infections in cancer patients: An international autopsy survey | European Journal of Clinical Microbiology and Infectious Diseases | 1992 | 542 |
| 5 | EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum | European Journal of Cancer | 2014 | 349 |
| 6 | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study | Lancet, The | 2017 | 307 |
| 7 | The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial | Radiotherapy and Oncology | 2000 | 292 |
| 8 | International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) | Annals of Oncology | 2017 | 249 |
| 9 | Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial | Nature Clinical Practice Oncology | 2006 | 222 |
| 10 | Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group | European Journal of Cancer | 2008 | 208 |
| 11 | The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ randomised trial | Radiotherapy and Oncology | 2004 | 145 |
| 12 | Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group | European Journal of Cancer | 2014 | 134 |
| 13 | Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials | Supportive Care in Cancer | 2011 | 133 |
| 14 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study | Lancet Oncology, The | 2021 | 132 |
| 15 | Gender medicine and oncology: report and consensus of an ESMO workshop | Annals of Oncology | 2019 | 120 |
| 16 | Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no boost” trial | International Journal of Radiation Oncology Biology Physics | 1999 | 116 |
| 17 | Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours | European Journal of Cancer | 2003 | 85 |
| 18 | Quality assurance for prospective EORTC radiation oncology trials: The challenges of advanced technology in a multicenter international setting | Radiotherapy and Oncology | 2011 | 80 |
| 19 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative | Cancer Discovery | 2021 | 79 |
| 20 | Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma | International Journal of Gynecological Cancer | 2014 | 75 |
| 21 | Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion | British Journal of Cancer | 1999 | 73 |
| 22 | Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years | Annals of Oncology | 2011 | 69 |
| 23 | Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials) | European Journal of Cancer | 2014 | 56 |
| 24 | Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy | Gynecologic Oncology | 2013 | 55 |
| 25 | Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review | Quality of Life Research | 2021 | 53 |
| 26 | Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. | Journal of Clinical Oncology | 2019 | 51 |
| 27 | Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis | European Journal of Cancer | 2017 | 50 |
| 28 | Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential | Applied Radiation and Isotopes | 2011 | 49 |
| 29 | The process of reconciliation: evaluation of guidelines for translating quality-of-life questionnaires | Expert Review of Pharmacoeconomics and Outcomes Research | 2012 | 49 |
| 30 | Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients | European Journal of Cancer | 2003 | 48 |
| 31 | Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC phase III trial 22931 | International Journal of Radiation Oncology Biology Physics | 2001 | 47 |
| 32 | An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients | Annals of Oncology | 2017 | 45 |
| 33 | Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin | Journal of Clinical Oncology | 2021 | 45 |
| 34 | Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971) | Journal of Clinical Oncology | 2004 | 43 |
| 35 | The First European Conference on Infections in Leukaemia – ECIL1: A current perspective | European Journal of Cancer | 2008 | 41 |
| 36 | Emerging good practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) measures | Journal of Patient-Reported Outcomes | 2018 | 40 |
| 37 | Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. | Journal of Clinical Oncology | 2013 | 39 |
| 38 | Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study | European Journal of Cancer | 2000 | 38 |
| 39 | Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens | Annals of Oncology | 2005 | 37 |
| 40 | Parenchymal sparing surgery brings treatment of colorectal liver metastases into the precision medicine era | European Journal of Cancer | 2018 | 37 |
| 41 | Public awareness about risk factors could pose problems for case-control studies: The example of sunbed use and cutaneous melanoma | European Journal of Cancer | 2005 | 35 |
| 42 | Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works | Strahlentherapie Und Onkologie | 2006 | 35 |
| 43 | Academia–Industry Partnerships: Are we ready for new models of partnership? | European Journal of Cancer | 2013 | 35 |
| 44 | Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study | European Journal of Cancer | 2014 | 34 |
| 45 | Activity of the dolastatin analogue, LU103793, in malignant melanoma | Annals of Oncology | 2001 | 33 |
| 46 | Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review | European Journal of Cancer | 2004 | 32 |
| 47 | Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey | Annals of Oncology | 2015 | 31 |
| 48 | Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study | Journal of Clinical Oncology | 2004 | 31 |
| 49 | Estimating Number of Events from the Kaplan-Meier Curve for Incorporation in a Literature-Based Meta-Analysis: What You Don't See You Can't Get! | Biometrics | 2000 | 30 |
| 50 | The Use of The Eortc Item Library To Supplement Eortc Quality of Life Instruments | Value in Health | 2017 | 27 |
